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Abstract
In most cancers harboring Ccdc6 gene rearrangements, like papillary thyroid tumors or myeloproliferative disorders, the
product of the normal allele is supposed to be functionally impaired or absent. To address the consequence of the loss of
CCDC6 expression, we applied lentiviral shRNA in several cell lines. Loss of CCDC6 resulted in increased cell death with clear
shortening of the S phase transition of the cell cycle. Upon exposure to etoposide, the cells lacking CCDC6 did not achieve
S-phase accumulation. In the absence of CCDC6 and in the presence of genotoxic stress, like etoposide treatment or UV
irradiation, increased accumulation of DNA damage was observed, as indicated by a significant increase of pH2Ax Ser139.
14-3-3s, a major cell cycle regulator, was down-regulated in CCDC6 lacking cells, regardless of genotoxic stress.
Interestingly, in the absence of CCDC6, the well-known genotoxic stress-induced cytoplasmic sequestration of the S-phase
checkpoint CDC25C phosphatase did not occur. These observations suggest that CCDC6 plays a key role in cell cycle
control, maintenance of genomic stability and cell survival and provide a rational of how disruption of CCDC6 normal
function contributes to malignancy.
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Introduction
Coiled-coil domain containing 6 (CCDC6, also known as H4/
D10S170 or PTC1) encodes for a ubiquitously expressed protein,
highly conserved across species, that is frequently rearranged in
human malignances. It was initially isolated and characterized due
to its participation in RET/PTC1 oncogene, the product of
inversion inv(10)(q11.2q21) which is present in approximately 20%
of papillary thyroid carcinoma (PTC) cases [1]. It also forms H4/
PDGFRb, the fusion gene product of the translocation
t(5;10)(q33;q22), occurring in sporadic cases of atypical chronic
myeloid leukemia [2–4].
The oncogenic activity of CCDC6 fusion proteins has been
demonstrated in vitro and in vivo [3,5,6]. There is compelling
evidence showing that RET/PTC rearrangements are early
genetic events in the process of cancer formation [7–9]. The
presence of RET/PTC1 in adenomas and benign tumors [10–12]
indicates that RET/PTC1 probably acts synergistically with other
factors that lead to malignancy. Interestingly, the vast majority of
PTC bearing RET/PTC1 failed to express wild type CCDC6
from the non-rearranged allele, suggesting a potential tumor
suppressor function of this gene [10]. In addition, in cases
expressing the normal allele, CCDC6 seems to be functionally
impaired through heterodimerization with the coil-coiled domain
of the fusion protein [13,14]. These data indicated that loss of
normal CCDC6 might support oncogenic transformation. More-
over, normal CCDC6 might be a positive regulator of apoptotic
cell death [14,15]. Furthermore, recent work has suggested that
CCDC6 might be functionally implicated in the cellular DNA
damage response [15]. To study the functional consequences of
loss of CCDC6 we applied a highly efficient lentiviral shRNA
knock down strategy in several human cancer cell lines. We found
that loss of CCDC6 resulted in distinct S-phase cell cycle defects,
increased genomic instability and cell death.
Results
Efficient CCDC6 silencing alters proliferation rate and
significantly increases cell death
Two lentiviruses expressing different CCDC6 shRNAs were
applied to HCT116, HeLa and MCF7 cells. As show in
Figure 1A, expression of either shRNA, resulted in highly
significant reduction of the protein levels of CCDC6. The impact
of CCDC6 knock down on proliferation and survival of HCT116
cells was studied by trypan blue dye exclusion and counting the
number of alive and dead cells for 4 consecutive days (Figure 1B).
A slight growth reduction of CCDC6 knock down cells was
observed compared to mock transduced control cells. The reduced
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(72 hours: rsh1=9.7 10
213, rsh2=3.8 10
207 and 96 hours:
rsh1=9.1 10
207, rsh2=2.4 10
208), suggesting that cells were not
growth arrested but rather cycling before cell death (Figure 1B).
To further investigate the observed cell death, we performed flow
cytometry gating for the cell population in subG0/G1 with less than
2n DNA content, corresponding to apoptotic and dead cells
(Figure 1C). This population was significantly increased (48 hours:
rsh1=2.8 10
24, rsh2=8.19 10
25,7 2 h o u r s :rsh1=0.0318,
rsh2=0.0259, 96 hours: rsh1=0.011, rsh2=3.9 10
24) upon
CCDC6 knock down compared to the control cells, at all time
points measured. We further analyzed apoptotic cell death by
staining for Po-PRO and 7-AAD. The double positive population
corresponding to lateapoptosiswas significantly increased (48 hours:
rsh1=0.001853, rsh2=0.003125, 72 hours: rsh1=0.006971,
rsh2=0.000968) in CCDC6 knock down cells, furthermore
suggesting that efficient silencing of CCDC6 results in apoptotic
cell death. Similar results were obtained in MCF7 and HeLa cells
(data not shown). Consequently, we demonstrated that absence of
CCDC6 results in increased cell death without growth arrest.
Loss of CCDC6 expression results in aberrant S-phase cell
cycle progression
To study the effect of CCDC6 knock down on cell cycle
progression, we transduced HCT116 and HeLa cells with the
shRNA expressing lentiviruses and analyzed cell cycle progression
of the cells by PI staining, at 48, 60, 72 and 84 hours. As shown in
Figure 2, alterations of all phases of the cell cycle could be
observed. More specifically, we observed a consistent increase of
the cell population in phases G1 and G2 and a decrease of cells in S
phase of the cell cycle at all time points upon CCDC6 knock
down, compared to mock-transduced cells. Similar results were
observed both in HCT116 (Figure 2A & B) and in HeLa cells
(Figure 2C & D).
To clarify the impact on cell cycle regulation we synchronized
HCT116 cells by serum starvation for 48 hours and re-stimulated
Figure 1. CCDC6 knock down alters proliferation rate and increases cell death in vitro. Cells were transduced using lentivirus, expressing
two different small hairpins for CCDC6, labeled as sh1 and sh2 and cultured for 48 hours. The same viral vector was applied as control (mock: mock
transduced). (A) Western blot analysis using anti-CCDC6 mouse monoclonal antibody demonstrated the efficient knock down of CCDC6 protein
expression. Growth curves were performed in triplicates using trypan blue dye exclusion for counting the alive (B) and the dead cells (C). Decreased
proliferation rate and increased cell death was observed in the absence of CCDC6. (D) The subG0/G1 population, as measured by flow cytometry, is
indicative of apoptosis and is significantly increased following CCDC6 knock down. The percentage of survival was calculated for each time point by
excluding both early apoptotic and dead cells. (E) Apoptotic cell death was analyzed by Po-PRO and 7-ADD staining. The Po-PRO single-positive cells
are early apoptotic while the double positive stained cells for Po-PRO and 7-AAD are late apoptotic and dead cells. All assays were performed in three
independent experiments.
doi:10.1371/journal.pone.0031007.g001
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zation of the mock-transduced control cells was superior to that
obtained by the CCDC6 knock down cells (Figure 2E). More
specifically, the majority of the mock-transduced cells were arrested
in G1 phase (84%) while a very small percentage of the cells was
distributed among S (6%) and G2 phase of the cycle (4%), as
expected. In contrast, upon CCDC6 knock down, the cells were
mainly in G1 (78%), with a respectful 22% of cells in G2; cells in S
phase were nearly undetected (1%). Moreover, 14 hours after serum
re-stimulation, the majority (<90%) of the control cells was in the S
phase whereas cells lacking CCDC6 exhibited a delay in G1/S
transition. However, 4 hours later, both control and knock down
cells demonstrated a similar profile. 24 hours afterserum stimulation
CCDC6 knockdowncells accumulatedinG1 and G2 of the cycle. At
the latter time point, the control cells were cycling normally
(Figure 2E). Taken together, these observations suggest that
regulation of cell cycle is significantly affected by CCDC6 silencing,
and the proper transition of cells through the S phase is disturbed.
Loss of CCDC6 expression inhibits intra-S phase
checkpoint activation and results in increased cell death
The impact of CCDC6 on S-phase cell cycle progression was
further addressed by treating mock-transduced and CCDC6
shRNA expressing HCT116 and HeLa cells with etoposide
(20 mM), a well-established topoisomerase II inhibitor inducing
DNA damage. Etoposide is known to activate intra-S phase
checkpoint control depicted as a delay in S phase, followed by a
G2/M arrest via activation of G2/M checkpoint [16–18].
Etoposide treatment of mock-transduced cells resulted in an initial
accumulation in S phase, as early as 4 hours after etoposide
addition, gradually reaching a G2 arrest 36 hours post treatment.
In contrast, CCDC6 knock down cells showed a dramatic
reduction of S phase accumulation, at all time points
(Figure 3A). Eventually, the cells progressed and accrued in G2
phase, exhibiting increased cell death compared to the control.
This was evidenced by the percentage of cells in subG0/G1,
reaching 22.7% for knock down cells compared to 9.0% of mock
transduced cells (Figure 3A & 3B). These results strongly
suggested that the presence of CCDC6 is essential for the proper
function of intra-S phase checkpoint control.
To determine the effect of CCDC6 silencing on cell survival
upon etoposide-mediated genotoxic stress, the apoptotic cells were
determined by Po-PRO and 7-AAD double stains. As depicted in
Figure 3C, CCDC6 knock down resulted in a significant decrease
of cell survival at 24 hours post etoposide treatment whereas the
survival of control cells remained unaffected upon etoposide
Figure 2. Normal Cell cycle progression is altered upon CCDC6 knock down. Cell cycle analysis was performed using propidium iodide (PI)
staining and measuring the DNA content, at the indicated time points, starting 48 hours after transduction. Cell cycle was analyzed with FlowJo
software and Jean-Fox algorithm. In all time points both in HCT116 (A), (B) and HeLa (C), (D) the percentage of cells in the S phase is reduced upon
knock down of CCDC6 in comparison to the control (mock). One, out of three, representative experiment is shown. (E) HCT116 cells were
synchronized by serum starvation for 48 hours followed by restimulation with 5% of FCS. CCDC6 knock down resulted in incomplete arrest at G1 and
not total synchronization, as the control cells. 14 hours after serum stimulation the majority of the control cells are in S phase while CCDC6 knock
down cells demonstrated a delay in S phase entering. 4 hours later, control and CCDC6 knock down cells showed the same profile, suggesting
shorter duration of S upon CCDC6 knock down. 24 hours later, control cells were cycling normally and CCDC6 knock down cells exhibited a delay in
completing G2 phase and re-entering G1.
doi:10.1371/journal.pone.0031007.g002
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down cells remained significant at 48 hours, while at 72 hours it
was eliminated, as expected, due to the etoposide toxicity. As cells
lacking proper S phase checkpoint regulation, accumulate DNA
damage and eventually die, these observations support the
necessity of CCDC6 for the proper function of the intra-S phase
checkpoint control.
CCDC6 knockdown increases susceptibility to UV-
induced DNA damage
To further investigate the contribution of CCDC6 to intra-S
phase cell cycle checkpoint, we applied genotoxic stress using UV
irradiation. Previous studies have shown that UV exposure leads to
the activation of an intra-S phase checkpoint that senses double
strand brakes (DSB) and triggers a signaling cascade of cellular
repair. The expected impact on the cell cycle profile is a delay of
completion of S phase leading to transient accumulation in S
phase. DNA damage beyond repair capacity results in G2 arrest,
cell death or senescence [19]; [20]. In this context, we treated
HCT116 and HeLa cells with UV-C in a DSB inducing dosage
0,002 J/cm
2 and followed cell cycle progression with and without
CCDC6 knock down. As expected, UV exposure of mock-
transduced cells resulted in an increased population of cells in the
G1 and S phase (Figure 4A). In contrast, upon shRNA-mediated
CCDC6 knock down the cells did not accumulate in G1/S phase
but continued cycling and entered G2 prematurely, suggesting that
the UV-induced intra-S-phase checkpoint was impaired.
Moreover, CCDC6 knock down cells were more susceptible to
UV-induced cell death compared to the controls, as determined
by calculating the subG0/G1 population after PI staining. <35%
of the knock down cells recorded in subG0/G1 while the control
cells remained below 10% (Figure 4B), resulting in impaired cell
survival (Figure 4C) reaching 60% from the initial 80%,
24 hours after treatment. In the latter time point, cell survival
of control cells was unaffected. To follow DSBs induced by either
UV irradiation or etoposide treatment, we also determined the
expression of pH2Ax Ser139, an established marker for DSBs in
the genome [21]. Loss of CCDC6 expression resulted in
increased pH2Ax Ser139 levels upon irradiation with abundant
expression as early as 2 hours post UV treatment. At the same
time point, pH2Ax Ser139 levels remained undetectable in mock-
transduced control cells. Overall, in all time points analyzed, the
pH2Ax Ser139 protein levels were higher in the absence of
CCDC6 expression (Figure 4D). Likewise, upon etoposide
treatment, the pH2Ax Ser139 protein levels were elevated in
the absence of CCDC6 (Figure 4D). Additionally, we visualized
pH2Ax Ser139 expression by confocal microscopy and demon-
strated that the levels of pH2Ax Ser139 were elevated upon
knock down of CCDC6 expression in accordance to the Western
blot results. Moreover, the nuclear configuration of this protein
changed in the absence of CCDC6, pH2Ax Ser139 forming
distinct foci. These observations furthermore suggest that
CCDC6 knock down increases susceptibility to DNA damage
upon genotoxic stress.
Figure 3. Deficient S phase checkpoint regulation upon etoposide treatment in the absence of CCDC6. (A) HCT116 cells were treated
with 20 mM etoposide and cells were harvested at predetermined time points for cell cycle analysis. In the absence of CCDC6, no S phase
accumulation is observed and the transition to G2 phase is accelerated. One representative experiment is shown, out of three performed. (B)
Concomitant apoptotic cell death was quantified by measuring the subG0/G1 DNA content. CCDC6 knock down cells showed higher levels of
apoptosis, at earlier time point, in comparison to the control, in response to genotoxic stress upon etoposide treatment. (C) The percentage of cell
survival was assessed by gating for PoPRO and 7-AAD negative cells. CCDC6 knock down resulted in lower cell survival upon etoposide induced
genotoxic stress. The assays were performed in triplicates.
doi:10.1371/journal.pone.0031007.g003
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regulators of G2/M transition
The above results demonstrate that CCDC6 contributes to the
activation of the S phase checkpoints. Due to its absence there is
acceleration to S phase and premature entrance to G2/M. The
transition to G2/M during normal cell cycle is regulated by the
activation of CDC25C. Previous studies have shown that, inactive
Ser216-phosphorylated CDC25C is sequestered to the cytoplasm
by the 14-3-3 proteins. Once mitosis is activated, cytoplasmic
sequestration of CDC25C is inhibited by a CDC2-mediated
phosphorylation of CDC25C at Ser214, leading to disassociation
of 14-3-3s and CDC25C [22–25].
We followed these S-phase checkpoint mediators, CDC25C and
14-3-3s, upon exposure of HCT116 cells to etoposide (20 mM), in
the presence or absence of CCDC6 using Western blotting and
confocal microscopy. As shown in Figure 5A, CDC25C is steadily
increased in a course of time, upon etoposide treatment. However,
CCDC6 knock down resulted in an earlier increase of the
CDC25C protein levels compared to mock-transduced cells.
Moreover, in CCDC6 knockdown the protein levels of 14-3-3s
decreased and then increased upon etoposide treatment. In
contrast, in mock-transduced cells the 14-3-3s levels remained
unchanged for 24 hours. More interestingly, absence of CCDC6
altered the localization of these molecules (Figures 5B & C).
More specifically, we followed the subcellular localization of
CDC25C upon etoposide treatment at different time points (0, 4,
8, 12, 24, 48 hours). Cytosolic sequestration of CDC25C in cells
lacking CCDC6 was not obvious in any of the time points checked
whereas mock-transduced cells exhibit mainly cytosolic localiza-
tion of CDC25C between 8 and 12 hours upon etoposide
treatment (Figure 5B). In further detail, as shown in
Figure 5C, in mock-transduced cells, CDC25C cytoplasmic
localization was accompanied with significant interactions with 14-
3-3s as indicated by the numerous sites of co-localization (seen in
yellow). Upon CCDC6 knockdown 14-3-3s signals were cytosolic
and down regulated and CDC25C main localization after
etoposide treatment (12 hours) was found in the nucleus without
any signs of co-localization with 14-3-3s observed.
Figure 4. Knock down of CCDC6 increases vulnerability to genotoxic stress by UV induced DNA damage. HCT116 cells were transduced
with CCDC6 shRNA expressing lentivirus or empty control followed by UV irradiation (0.002 J/cm
2), 48 hours after transduction. Cells were harvested
at 2, 6 and 24 hours after irradiation and analyzed for the cell cycle using flow cytometry. The percentages of the cell populations in each phase of
the cell cycle for every time point are depicted as bars in the diagram (A). In control cells, UV irradiation results in G1 and S phase increase while in
CCDC6 knock down cells UV irradiation causes a reduction of cell population in S phase and an increase in G2 phase. A representative experiment is
shown. (B) The apoptotic levels were measured by flow cytometric assessment of the subG0/G1 population. Knock down of CCDC6 increase UV-
mediated cell death. (C) Cell survival analysis by Po-PRO and 7-ADD staining (excluding the double positive cells) revealed a significantly decreased
cell survival of cells lacking CCDC6. Error Bars represent 3 independent experiments. (D) Cell lysates of HCT116 cells treated with etoposide (20 mM) or
radiated with UV (0.002 J/cm
2) for 2, 6 or 24 hours and the untreated controls were resolved on a SDS-PAGE and probed for pH2Ax Ser139. Upon UV
irradiation, pH2Ax Ser139 levels arise earlier and to a higher extent in CCDC6 knock down cells compared to the control. UV irradiation is causing high
levels of pH2Ax Ser139 even in 2 hours after irradiation in CCDC6 knock down cells. The effect is similar upon etoposide treatment, although less
dramatic. (E) Increased basal levels and nuclear foci of pH2Ax Ser139 are present in CCDC6 knock down cells, even in the absence of any additional
treatment.
doi:10.1371/journal.pone.0031007.g004
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Several lines of evidence suggested that CCDC6-related
malignancies are developed upon loss of CCDC6 normal
function. First, the majority (.90%) of tumors bearing CCDC6
fusion genes do not express CCDC6 from the normal allele [10].
In addition, in the presence of the chimeric molecule,
endogenous expressed normal CCDC6 protein seems to hetero-
dimerize with the fusion product, suggesting a dominant negative
effect of the fusion on CCDC6 normal function [13,26].
Moreover, several public databases reported that a significant
number of head and neck cancers exhibit considerable down-
regulation of CCDC6 (www.oncomine.org, www.proteinatlas.
org). Under this perspective, we have silenced expression of
CCDC6 in several cell lines using a highly efficient shRNA
knockdown strategy. Loss of CCDC6 resulted in apoptotic cell
death with only a minor reduction in proliferation. We also
reported that CCDC6 is important for normal cell cycle
progression and proper function of checkpoint controls. In the
absence of CCDC6, intra S phase control was deficient and this
Figure 5. CCDC6 knock down results in altered cellular localization of CDC25C and accelerated G2/S transition upon etoposide-
mediated genotoxic stress. Control and CCDC6 knock down HCT116 cells were treated with etoposide (20 mM). (A) Cell lysates of HCT116 cells
treated with etoposide (20 mM) for 2, 4, 8, 12 and 24 hours and mock control treated with DMSO vehicle were resolved on a SDS-PAGE and probed
for 14-3-3s and CDC25C. 14-3-3s protein levels were down-regulated in the absence of CCDC6 protein expression and the CDC25C protein level
regulation was altered. (B) Cells grown on cover slips were exposed to etoposide for 4, 8, 12, 24 hours, fixed and stained for CDC25C. In mock cells,
CDC25C is kept in the cytosol upon etoposide treatment at 8 and 12 hours but is localized in the nucleus in the absence of CCDC6. (C) Cells exposed
to etoposide for 12 hours were co-stained for CDC25C and 14-3-3s. CDC25C is kept in the cytosol upon etoposide treatment and exhibits co-
localization with 14-3-3s (seen in yellow) but enters the nucleus in the absence of CCDC6.
doi:10.1371/journal.pone.0031007.g005
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UV-irradiation.
A key regulator of the S phase duration and the transition to G2
is 14-3-3s and its complexes to several partner proteins. 14-3-3-
ligand association triggers a phosphorylation cascade resulting in
cytoplasmic sequestration of the CDC25-B, CDC25-C phospha-
tases. Due to their location, the latter are kept inactive and unable
to reach their targets, Cdk1/cyclin B1 and MPF complexes [27];
[28]. Upon loss of CCDC6, we observed downregulation of 14-3-
3s and altered regulation and localization of CDC25C. In fact,
CDC25C enters the nucleus, were it triggers mitosis by activation
of the Cdk1/cyclin B complex. These observations suggest that
CCDC6 is implicated in the regulation of normal both cell cycle
progression and DNA repair mechanisms most probably through
co-operation with 14-3-3s. Interestingly, a recent proteomics
study proposed direct physical interaction of CCDC6 with 14-3-
3s in a PI3K kinase specific manner [29].
Cell cycle checkpoints are implemented to safeguard the
genome from accumulation of genetic errors. S (synthesis) phase
is undoubtedly the most vulnerable period of the cell cycle division
[30] and its checkpoints are the most significant for preventing
genetic instability [31]. Extensive literature shows that malfunc-
tioned S phase and thus aberrant DNA replication can lead to
increased mutagenesis and also cell death in mitosis [32]. The fact
that CCDC6 is highly implicated in chromosomal rearrangements
could be an additional link to its role in genomic stability and
supports our findings concerning S phase deficiency upon loss of
CCDC6 [33]. The spatial contiguity between CCDC6 and RET
and also their location at DNA fragile sites have been accused for
the high frequency of RET/PTC1 rearrangements [34–36]. Our
data suggest, that loss of CCDC6 function can create a prosperous
environment for the formation of cancer [15,26,37,38]. Cells
depleted for CCDC6 show increased cell death in presence or
absence of genotoxic stress. These cells do not arrest in G1 or S
phase upon DNA damage as expected. They proceed with DNA
synthesis resulting in accumulation of DNA damage, as demon-
strated by an increase of pH2Ax S139 protein levels. Our results
are in agreement with previous work showing that CCDC6 down-
regulation and treatment with c-radiation resulted in increased
BrdU incorporation and staining for the pH3 mitosis marker [15].
However, increased genotoxic stress-mediated DNA damage and
cell death upon CCDC6 knock down cells has not been observed
in the latter study. This discrepancy might be due to the higher
knock down efficiency in the here presented experiments where
the protective effects of CCDC6 were abolished.
Interestingly, similar cell cycle effects phenocopying CCDC6
knock down have been previously reported in leukemic cells
expressing the BCR/ABL tryrosine kinase fusion oncoprotein
[39,40]. In fact expression of BCR/ABL seems also to increase
DNA double-strand damage after etoposide treatment and lead to
a defect in an intra-S phase checkpoint. Therefore, it will be
interesting to study whether expression of the PTC1 oncogenic
tyrosine kinase results in similar cell cycle checkpoint defects.
Therefore, additional studies should be performed to address
whether loss of normal CCDC6 might be a more common
principle for other constitutively active oncogenic kinase fusions
beyond the CCDC6 fusions to RET or PDGFR.
Taken together, our work suggests that loss of CCDC6 results in
S phase deregulation that impairs the ability of the cell to maintain
genomic integrity and creates a prosperous ground for genomic
instability [30,41–43]. Further specification of the exact pathways
in which CCDC6 is implicated and identification of its interacting
partners will be necessary to unravel the molecular mechanisms of
cancers, harboring CCDC6 alterations.
Materials and Methods
Cell culture and treatments
Different cell lines, such as HCT116, HeLa, MCF7 and 293T
were cultured as a monolayer in Dulbecco’s Minimal Essential
Medium (DMEM) supplemented with 10% Fetal Calf Serum,
1%P/S and 1% L-Glutamine (Invitrogen, Paislay, UK). The cells
were incubated at 37uC and 5% CO2.
Synchronisation of HCT116s was achieved through serum
deprivation for 48 hours. The cells were plated on a 6 well plate
(3610
5 cells/well) and stimulated with DMEM supplemented with
5% of FCS. They were harvested at the indicated time points and
the cell cycle was analysed.
Cells in culture were UV irradiated at 0.002 J/cm
2 using a
254 nm lamp of a UV Stratalinker 2400 (Stratagene/Agilent
Technologies, Santa Clara, CA, USA).
Cells were treated with 20 mM etoposide (Sigma/Aldrich, St.
Louis, MO, USA) for the selected time points and cell cycle and
apoptotic assays were performed.
Lentiviral shRNA constructs, viral production and cell
transduction
Silencing of Ccdc6 was accomplished using commercially
available shRNA lentiviral based constructs (TRCN 0000083831
and TRCN0000083828) from Sigma (Sigma/Aldrich, St. Louis,
MO, USA). The empty lentiviral vector TRC1 (Sigma/Aldrich,
St. Louis, MO, USA) was applied as a control.
For the lentiviral supernatant production, HEK-293T cells
maintained in DMEM supplemented with 5% FCS without
antibiotics, on 10 cm culture plates to ,60% confluency. Sixteen
hours later transfection of HEK-293T cells took place. As a
transfection reagent Lipofectamine (Invitrogen, Carlsbad, CA,
USA) was used according to the manufacture’s protocol. 3 mgo f
the envelop plasmid pMD2G,3 mg of the packaging plasmid
pMDLpRRE, 2.5 mg of the Rev-expression plasmid pRSV/Rev
(Addgene, Cambridge, MA, USA) and 10 mg of the shRNA
lentiviral construct were added in 1 mL of DMEM medium,
serum and antibiotics free. 40 mL of lipofectamine was diluted in
1 mL of DMEM without serum and antibiotics and incubated for
5 min. DNA and lipofectamine parts were mixed and incubated
for 20 min before added to the HEK293T cells. 24 hours later, the
medium was discarded and replaced with 5 mL of DMEM with
10% FCS, without antibiotics. 24 hours later the medium was
collected into a 15 mL tube and 5 mL of medium were added to
the plate and the same step was repeated at 48 hours. The
lentivirus-containing supernatant was filtered through a 20 mM
pore filter, aliquoted to 1 mL cryotubes and quickly frozen down
in liquid nitrogen. Virus was stored at 280uC.
HCT116s, HeLas and MCF7s were plated in 6 well plates (5
10
5 cells/well) and 16 hours later were viral transduced. This was
performed using 1 mL of lentiviral supernatant, diluted in 1 mL of
DMEM complete medium and 4 mL of protein sulphate. Cells
were centrifuged at 2,500 rpm (Heraeus Biofuge stratos centrifuge)
for 90 min at RT. The medium was replaced with fresh complete
DMEM and changed again 24 hours later.
Fixation and immunostaining
Cells were cultured on cover slips, coated with polylysine.
Fixation was performed in 4% paraformaldehyde (Sigma/Aldrich,
St. Louis, MO, USA) solution in PBS, incubated for 10 min at
RT. The excess paraformaldehyde was discarded after washing
the cells three times with PBS. Permeabilisation was achieved
through incubation in 0.1% Triton–X 100 solution for 10 min and
then in 0.5% Triton-X 100 (Sigma/Aldrich, St. Louis, MO, USA)
CCDC6 Is Implicated in Cell Cycle Regulation
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solution for 1 hour. Incubation was performed for 16 hours at 4uC
in a solution containing 0.3% Triton-.X100, 0.5% BSA and the
indicated primary antibody in the appropriate dilution. After
washing three times with 0.3% Triton-X in PBS, cells were
incubated with the secondary antibody diluted in 0.5% Triton-X
in PBS and 0.5% BSA for 2 hours. The cells were washed on the
cover slips and put on a slide by adding on top a droplet of
clearnoutmounting medium (Invitrogen, Carlsbad, CA, USA).
The secondary antibodies used were anti-goat FITCH from
ZYMED, anti-mouse Alexa 555, anti-rabbit Alexa 488 from
Invitrogen (Invitrogen, Carlsbad, CA, USA).
Flow cytometric analysis
Cell death and apoptosis was measured by Membrane
Permeability/Dead Cell Apoptosis Kit with Po-PRO-1 and 7-
AAD Apoptosis for Flow Cytometry (Invitrogen, Carlsbad, CA,
USA) as recommended by the manufacturer, using a DAKO
CYAN flow cytometer (DAKO, Fort Collins, CO, USA). Cell
cycle profiling was carried out by Propidium Iodide staining and
analysed by FlowJo Software. The quantification of apoptosis was
performed via analysis of the subG0. Cells were fixed with 70% ice
cold ethanol and kept at 220uC over night. Then, cells were
washed twice with PBS and resuspended in PI solution containing
1 mg/mL propidium iodide, 100 mg/mL RNase A, 0.001%
Triton-X 100 in PBS at a concentration of 10
6 cells/mL,
incubated for 45 min at 37uC in the dark and analysed using a
Dako CYAN FACS machine. The propidum iodide fluorescence
emission signal was detected in the FL3 channel. At least 20,000
events were acquired.
Confocal microscopy
Confocal fluorescence images were obtained by a Zeiss LSM710
(Zeiss, Thornwood, NY microscope) with a 636objective. Images
were analysed by Zeiss software.
Antibodies and Western Blot analysis
Cells were harvested and lysed in RIPA (200 mM NaCl,
10 mM Tris-Hcl at pH 7.5, 0.1% SDS, 1%Triton X-100) and
complete protease and phosphatase inhibitor cocktail tablets
(Hoffmann-La Roche NJ, USA). The protein concentration was
determined by a Bradford assay (BIORAD). Equal amounts of
proteins were electrophorated and separated by 12% SDS-PAGE
gels, followed by transfer onto nitrocellulose membranes. Immu-
noblotting was performed using various antibodies. Blotted
proteins were visualized with the aid of an enhanced chemilumi-
nescence kit (Amersham, Piscataway, NJ, USA) and imaged with
Kodak Biomax Light Films (Sigma/Aldrich, St. Louis, MO, USA).
Antibodies were as follows: Anti-Ccdc6 (ab-56353), 14-3-3s
(ab1423) from Abcam (Abcam, Cambridge, UK), anti Cdc25C (sc-
327), anti-actin (sc-1615) and anti pH2Ax Ser139 (07-164,
Upstate) from Cell Signaling (Beverly, MA, USA). The secondary
antibodies were: anti-mouse, anti rabbit and anti-goat HRP
conjugated from ThermoScientific.
Statistic analysis
Inter-group comparison was performed using a paired two
sample t-test. The minimum level of statistical significance was set
at aJ0.05.
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